Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Phys Med Rehabil. 2013 Aug;92(8):728-33. doi: 10.1097/PHM.0b013e318282d209.

Treatment of classic pantothenate kinase-associated neurodegeneration with deferiprone and intrathecal baclofen.

Author information

1
Pediatric Clinical Research Center, Children's Hospital and Research Center, Oakland, California 94609, USA.

Abstract

Neurodegeneration with brain iron accumulation (NBIA) describes a heterogeneous family of diseases characterized by high brain iron, particularly in the basal ganglia. The most common manifestation of childhood NBIA is classic pantothenate kinase-associated neurodegeneration (PKAN), a severe, progressive type of autosomal recessive neuroaxonal dystrophy characterized by early onset of symptoms (as opposed to atypical PKAN, with an average age of onset of 14 yrs). There is currently no established therapy for the disease. Intrathecal baclofen has been reported to improve ease of care and dystonia in patients with PKAN. Deferiprone, an iron chelator, has been shown to be safe and tolerable in patients with PKAN as well as effective in reducing brain iron accumulation, as measured by magnetic resonance imaging. This case report highlights the potency of combining intrathecal baclofen and oral deferiprone in a patient with classic PKAN. Although treatment with deferiprone alone was not attempted, this combination therapy seems to be more efficacious than treatment with only intrathecal baclofen.

PMID:
23370589
PMCID:
PMC3707939
DOI:
10.1097/PHM.0b013e318282d209
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer Icon for PubMed Central
    Loading ...
    Support Center